Dyne Therapeutics, Inc. Stock Prediction and Forecast [DYN]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 28 Oct 2025, 02:59 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Dyne Therapeutics, Inc. Stock Prediction and Forecast [DYN]](https://i.ytimg.com/vi/AVzou3mQ7zE/hqdefault.jpg)
AI-generated source summary
The video analyzes Dyne Therapeutics (DYN) stock, downgrading it from "strong buy" to "hold". The analysis highlights the stock's recent significant gains, achieving 73.26% in 15 days with an average daily gain of 4.88%, despite the system assigning a score of zero, predicting high volatility and risk. It notes the stock's recent break through an upward trend, estimating a potential 53.6% change in the next three months, with returns ranging from a decline of 9.13% to an increase of 12.44%. The 12-month analysis projects a change of -37.7%, suggesting a future price range of 0.00 to 15.06. Analyst ratings average to "sell". On the last trading day, DYNE gained 41.18%, closing at 24.17, and volume has increased on the last day along with the price, which is considered to be a good technical signal. Support is now at $17.76. There are ongoing investor litigation inquiries. The suggested stop-loss is $22.90 (-5.24%). For trading on October 28th, expect Dyne Therapeutics to open down -$0.130 and start trading at $24.04.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.